Efficacy and safety of Androgen Deprivation Therapy (ADT) combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a multicentre prospective randomized controlled trial

被引：0
|
作者：
Xiangwei Yang
Hong Chen
Duanya Xu
Xianju Chen
Yamei Li
Jun Tian
Dongwen Wang
Jun Pang
机构：
[1] Sun Yat-sen University,Department of Urology, Kidney and Urology Center, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital
[2] University of Hong Kong,School of Nursing, LKS Faculty of Medicine
[3] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital,undefined
[4] Chinese Academy of Medical Sciences and Peking Union Medical College,undefined
来源：
BMC Cancer | / 22卷
关键词：
Metastatic castration-resistant prostate cancer; Modified docetaxel chemotherapy; Androgen deprivation therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.
    Caffo, Orazio
    Palesandro, Erica
    Nole, Franco
    Gasparro, Donatello
    Mucciarini, Claudia
    Aieta, Michele
    Zagonel, Vittorina
    Iacovelli, Roberto
    De Giorgi, Ugo
    Rossetti, Sabrina
    Fratino, Lucia
    Sacco, Cosimo
    Nicodemo, Maurizio
    Giordano, Monica
    Sartori, Donata
    Scapoli, Daniela
    Verri, Elena
    Kinspergher, Stefania
    Pappagallo, Giovanni L.
    Aglietta, Massimo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [42] Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) by metastatic burden: Subgroup analyses of ARASENS
    Tombal, B.
    Saad, F.
    Fizazi, K.
    Sternberg, C. N.
    Crawford, E. D.
    Gratzke, C.
    Grabbert, M.
    Vilaseca, A.
    Shore, N.
    Kopyltsov, E.
    Boegemann, M.
    Kapur, S.
    Srinivasan, S.
    Verholen, F.
    Kuss, I.
    Joensuu, H.
    Smith, M. R.
    Hussain, M.
    EUROPEAN UROLOGY, 2023, 83
  • [43] 177Lu-PSMA-617 versus docetaxel in chemotherapy-naive metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial
    Satapathy, Swayamjeet
    Mittal, Bhagwant Rai
    Sood, Ashwani
    Das, Chandan Krushna
    Mavuduru, Ravimohan Suryanarayan
    Goyal, Shikha
    Shukla, Jaya
    Singh, Shrawan Kumar
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (05) : 1754 - 1764
  • [44] Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer
    Fizazi, Karim S.
    Higano, Celestia S.
    Nelson, Joel B.
    Gleave, Martin
    Miller, Kurt
    Morris, Thomas
    Nathan, Faith E.
    McIntosh, Stuart
    Pemberton, Kristine
    Moul, Judd W.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (14) : 1740 - +
  • [45] Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA
    Oudard, Stephane
    Fizazi, Karim
    Sengelov, Lisa
    Daugaard, Gedske
    Saad, Fred
    Hansen, Steinbjorn
    Hjalm-Eriksson, Marie
    Jassem, Jacek
    Thiery-Vuillemin, Antoine
    Caffo, Orazio
    Castellano, Daniel
    Mainwaring, Paul N.
    Bernard, John
    Shen, Liji
    Chadjaa, Mustapha
    Sartor, Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (28) : 3189 - +
  • [46] PSA response and early PSA progression evaluated in patients randomized in a phase III trial comparing androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in hormone-naive metastatic prostate cancer (GETUG-AFU 15/0403).
    Gravis, G.
    Fizazi, K.
    Joly, F.
    Oudard, S.
    Priou, F.
    Latorzeff, I.
    Delva, R.
    Esterni, B.
    Habibian, M.
    Soulie, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] FEASIBILITY AND SAFETY OF ABIRATERONE ACETATE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER DOCETAXEL-BASED CHEMOTHERAPY: A SINGLE CENTER EXPERIENCE
    Baki, Muhammed
    Detti, Beatrice
    Bonomo, Pierluigi
    Giacomelli, Irene
    Cappelli, Sabrina
    Poggesi, Linda
    Franceschini, Davide
    Carini, Marco
    Nicita, Giulio
    Serni, Sergio
    Baldazzi, Valentina
    Di Brina, Lucia
    Mancuso, Anna
    Monteleone, Eleonora
    Carta, Giulio Alberto
    Muntoni, Cristina
    Ciabatti, Cinzia
    Livi, Lorenzo
    ANTICANCER RESEARCH, 2015, 35 (06) : 3631 - 3632
  • [48] Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy
    M. Thalgott
    M. M. Heck
    M. Eiber
    M. Souvatzoglou
    G. Hatzichristodoulou
    V. Kehl
    B. J. Krause
    B. Rack
    M. Retz
    J. E. Gschwend
    U. Andergassen
    R. Nawroth
    Journal of Cancer Research and Clinical Oncology, 2015, 141 : 1457 - 1464
  • [49] Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy
    Thalgott, M.
    Heck, M. M.
    Eiber, M.
    Souvatzoglou, M.
    Hatzichristodoulou, G.
    Kehl, V.
    Krause, B. J.
    Rack, B.
    Retz, M.
    Gschwend, J. E.
    Andergassen, U.
    Nawroth, R.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (08) : 1457 - 1464
  • [50] Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial
    Zurita, A. J.
    George, D. J.
    Shore, N. D.
    Liu, G.
    Wilding, G.
    Hutson, T. E.
    Kozloff, M.
    Mathew, P.
    Harmon, C. S.
    Wang, S. L.
    Chen, I.
    Maneval, E. Chow
    Logothetis, C. J.
    ANNALS OF ONCOLOGY, 2012, 23 (03) : 688 - 694
12345